Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
EYP-651 by Enyo Pharma for Metabolic Dysfunction-Associated Steatohepatitis (MASH): Likelihood of Approval
EYP-651 is under clinical development by Enyo Pharma and currently in Phase II for Metabolic Dysfunction-Associated Steatohepatitis (MASH). According to...
EYP-651 by Enyo Pharma for Diabetic Nephropathy: Likelihood of Approval
EYP-651 is under clinical development by Enyo Pharma and currently in Phase I for Diabetic Nephropathy. According to GlobalData, Phase...
EYP-651 by Enyo Pharma for Chronic Kidney Disease (Chronic Renal Failure): Likelihood of Approval
EYP-651 is under clinical development by Enyo Pharma and currently in Phase II for Chronic Kidney Disease (Chronic Renal Failure)....
Vonafexor by Enyo Pharma for Chronic Kidney Disease (Chronic Renal Failure): Likelihood of Approval
Vonafexor is under clinical development by Enyo Pharma and currently in Phase II for Chronic Kidney Disease (Chronic Renal Failure)....
Vonafexor by Enyo Pharma for Alport Syndrome: Likelihood of Approval
Vonafexor is under clinical development by Enyo Pharma and currently in Phase II for Alport Syndrome. According to GlobalData, Phase...